The impact of IL28B genotype on the gene expression profile of patients with chronic hepatitis C treated with pegylated interferon alpha and ribavirin

Journal of Translational Medicine

Volumn 10, Issue 1, 2012, Pages

  Younossi, Zobair M ^a,b,c   Birerdinc, Aybike ^a,b   Estep, Mike ^a,c   Stepanova, Maria ^a,b,c   Afendy, Arian ^a,c   Baranova, Ancha ^a,b  

^a BETTY AND GUY BEATTY CENTER FOR INTEGRATED RESEARCH   (United States)

^b GEORGE MASON UNIVERSITY   (United States)

^c INOVA FAIRFAX HOSPITAL   (United States)

Author keywords

Chronic hepatitis C; Gene expression; HCV; HCV treatment; IL28B; IRF2; Pathway analysis; SOCS1

Indexed keywords

INTERLEUKIN 28B; PEGINTERFERON ALPHA; RIBAVIRIN; SUPPRESSOR OF CYTOKINE SIGNALING 1; ALPHA INTERFERON; ANTIVIRUS AGENT; IL28B PROTEIN, HUMAN; INTERFERON REGULATORY FACTOR 2; INTERLEUKIN DERIVATIVE; IRF2 PROTEIN, HUMAN; MACROGOL DERIVATIVE; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RECOMBINANT PROTEIN; SOCS1 PROTEIN, HUMAN; SUPPRESSOR OF CYTOKINE SIGNALING;

ADULT; AFRICAN AMERICAN; ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; DISEASE ASSOCIATION; DOWN REGULATION; DRUG TREATMENT FAILURE; ETHNIC DIFFERENCE; FEMALE; GENE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; GENE SILENCING; GENETIC ASSOCIATION; GENOTYPE; HEPATITIS C; HUMAN; INTERLEUKIN 28B GENE; MAJOR CLINICAL STUDY; MALE; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; SUPPRESSOR OF CYTOKINE SIGNALING 1 GENE; TREATMENT DURATION; COHORT ANALYSIS; DRUG EFFECT; GENETICS; METABOLISM; MIDDLE AGED; TIME; UPREGULATION; VIROLOGY;

ANTIVIRAL AGENTS; COHORT STUDIES; DOWN-REGULATION; FEMALE; GENE EXPRESSION PROFILING; GENOTYPE; HEPATITIS C, CHRONIC; HUMANS; INTERFERON REGULATORY FACTOR-2; INTERFERON-ALPHA; INTERLEUKINS; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; RECOMBINANT PROTEINS; RIBAVIRIN; SIGNAL TRANSDUCTION; SUPPRESSOR OF CYTOKINE SIGNALING PROTEINS; TIME FACTORS; UP-REGULATION;

EID: 84856565716     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/1479-5876-10-25     Document Type: Article

References (38)

1. Alter MJ. Epidemiology of hepatitis C virus infection. World J Gastroenterol 2007, 13:2436-2441.
2. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, Goodman ZD, Koury K, Ling M, Albrecht JK. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001, 358:958-965.
3. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL, Häussinger D, Diago M, Carosi G, Dhumeaux D, Craxi A, Lin A, Hoffman J, Yu J. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002, 347:975-978.
4. Neumann-Haefelin C, Spangenberg HC, Blum HE, Thimme R. Host and viral factors contributing to CD8+ T cell failure in hepatitis C virus infection. World J Gastroenterol 2007, 13:4839-4847.
5. Chen TY, Hsieh YS, Wu TT, Yang SF, Wu CJ, Tsay GJ, Chiou HL. Impact of serum levels and gene polymorphism of cytokines on chronic hepatitis C infection. Transl Res 2007, 150:116-121.
6. Younossi Z, McCullough A. Metabolic Syndrome, Non-Alcoholic Fatty Liver Disease and Hepatitis C Virus: Impact on Disease Progression and Treatment Response. Liver Int 2009, 29(Suppl. 2):3-12.
7. Sharma P, Marrero JA, Fontana RJ, Greenson JK, Conjeevaram H, Su GL, Askari F, Sullivan P, Lok AS. Sustained virologic response to therapy of recurrent hepatitis C after liver transplantation is related to early virologic response and dose adherence. Liver Transpl 2007, 13:1100-1108.
8. Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ, Heinzen EL, Qiu P, Bertelsen AH, Muir AJ, Sulkowski M, McHutchison JG, Goldstein DB. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009, 461(7262):399-401.
9. Thomas DL, Thio CL, Martin MP, Qi Y, Ge D, O'Huigin C, Kidd J, Kidd K, Khakoo SI, Alexander G, Goedert JJ, Kirk GD, Donfield SM, Rosen HR, Tobler LH, Busch MP, McHutchison JG, Goldstein DB, Carrington M. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 2009, 461(7265):798-801.
10. Thompson AJ, Muir AJ, Sulkowski MS, Ge D, Fellay J, Shianna KV, Urban T, Afdhal NH, Jacobson IM, Esteban R, Poordad F, Lawitz EJ, McCone J, Shiffman ML, Galler GW, Lee WM, Reindollar R, King JW, Kwo PY, Ghalib RH, Freilich B, Nyberg LM, Zeuzem S, Poynard T, Vock DM, Pieper KS, Patel K, Tillmann HL, Noviello S, Koury K, Pedicone LD, Brass CA, Albrecht JK, Goldstein DB, McHutchison JG. Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus. Gastroenterology 2010, 139(1):120-9. e18.
11. Suppiah V, Moldovan M, Ahlenstiel G, Berg T, Weltman M, Abate ML, Bassendine M, Spengler U, Dore GJ, Powell E, Riordan S, Sheridan D, Smedile A, Fragomeli V, Müller T, Bahlo M, Stewart GJ, Booth DR, George J. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet 2009, 41(10):1100-4.
12. Mangia A, Thompson AJ, Santoro R, Piazzolla V, Tillmann HL, Patel K, Shianna KV, Mottola L, Petruzzellis D, Bacca D, Carretta V, Minerva N, Goldstein DB, McHutchison JG. An IL28B polymorphism determines treatment response of hepatitis C virus genotype 2 or 3 patients who do not achieve a rapid virologic response. Gastroenterology 2010, 139(3):821-7. 827.e1.
13. Indolfi G, Sambrotta M, Moriondo M, Azzari C, Resti M. Genetic variation in IL28B locus is associated with spontaneous clearance of HCV in children with Non-1 viral genotype infection. Hepatology 2011,
14. Lindh M, Lagging M, Färkkilä M, Langeland N, Mørch K, Nilsson S, Norkrans G, Pedersen C, Buhl MR, Westin J, Hellstrand K. Interleukin 28B Gene Variation at rs12979860 Determines Early Viral Kinetics During Treatment in Patients Carrying Genotypes 2 or 3 of Hepatitis C Virus. J Infect Dis 2011, 203(12):1748-52.
15. Yu ML, Huang CF, Huang JF, Chang NC, Yang JF, Lin ZY, Chen SC, Hsieh MY, Wang LY, Chang WY, Li YN, Wu MS, Dai CY, Juo SH, Chuang WL. Role of interleukin-28B polymorphisms in the treatment of hepatitis C virus genotype 2 infection in Asian patients. Hepatology 2011, 53(1):7-13.
16. Rauch A, Kutalik Z, Descombes P, Cai T, Di Iulio J, Mueller T, Bochud M, Battegay M, Bernasconi E, Borovicka J, Colombo S, Cerny A, Dufour JF, Furrer H, Günthard HF, Heim M, Hirschel B, Malinverni R, Moradpour D, Müllhaupt B, Witteck A, Beckmann JS, Berg T, Bergmann S, Negro F, Telenti A, Bochud PY, . Swiss Hepatitis C Cohort Study; Swiss HIV Cohort Study Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. Gastroenterology 2010, 138(4):1338-45. 1345.e1-7, Swiss Hepatitis C Cohort Study; Swiss HIV Cohort Study.
17. Tillmann HL, Thompson AJ, Patel K, Wiese M, Tenckhoff H, Nischalke HD, Lokhnygina Y, Kullig U, Göbel U, Capka E, Wiegand J, Schiefke I, Güthoff W, Grüngreiff K, König I, Spengler U, McCarthy J, Shianna KV, Goldstein DB, McHutchison JG, Timm J, Nattermann J, . German Anti-D Study Group A polymorphism near IL28B is associated with spontaneous clearance of acute hepatitis C virus and jaundice. Gastroenterology 2010, 139(5):1586-92. 1592.e1, German Anti-D Study Group.
18. Grebely J, Petoumenos K, Hellard M, Matthews GV, Suppiah V, Applegate T, Yeung B, Marks P, Rawlinson W, Lloyd AR, Booth D, Kaldor JM, George J, Dore GJ, . ATAHC Study Group Potential role for interleukin-28B genotype in treatment decision-making in recent hepatitis C virus infection. Hepatology 2010, 52(4):1216-24. ATAHC Study Group.
19. Younossi ZM, Baranova A, Afendy A, Collantes R, Stepanova M, Manyam G, Bakshi A, Sigua CL, Chan JP, Iverson AA, Santini CD, Chang SY. Early gene expression profiles of patients with chronic hepatitis C treated with pegylated interferon-alfa and ribavirin. Hepatology 2009, 49(3):763-74.
20. Galmozzi E, Menico BD, Rametta R, Dongiovanni P, Fracanzani AL, Benedan L, Borroni V, Maggioni P, Fargion S, Valenti L. A tetra-primer amplification refractory mutation system polymerase chain reaction for the evaluation of rs12979860 IL28B genotype. J Viral Hepat 2010,
21. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001, 25:402-8.
22. Tang H, Grisé H. Cellular and molecular biology of HCV infection and hepatitis. Clin Sci 2009, 117:49-65.
23. Roe B, Hall WW. Cellular and molecular interactions in coinfection with hepatitis C virus and human immunodeficiency virus. Expert Rev Mol Med 2008, 10:e30.
24. Hayashi N, Takehara T. Antiviral therapy for chronic hepatitis C: past, present, and future. J Gastroenterol 2006, 41(1):17-27.
25. Muir AJ, Hu KQ, Gordon SC, Koury K, Boparai N, Noviello S, Albrecht JK, Sulkowski MS, McCone J. Hepatitis C treatment among racial and ethnic groups in the IDEAL trial. J Viral Hepat 2011, 18(4):e134-43.
26. Birerdinc A, Afendy A, Stepanova M, Younossi I, Manyam G, Baranova A, Younossi ZM. Functional pathway analysis of genes associated with response to treatment for chronic hepatitis C. J Viral Hepat 2010, 17(10):730-6.
27. Satapathy SK, Lingisetty CS, Proper S, Chaudhari S, Williams S. Equally poor outcomes to pegylated interferon-based therapy in African Americans and Hispanics with chronic hepatitis C infection. J Clin Gastroenterol 2010, 44(2):140-5.
28. Urban TJ, Thompson AJ, Bradrick SS, Fellay J, Schuppan D, Cronin KD, Hong L, McKenzie A, Patel K, Shianna KV, McHutchison JG, Goldstein DB, Afdhal N. IL28B genotype is associated with differential expression of intrahepatic interferon-stimulated genes in patients with chronic hepatitis C. Hepatology 2010, 52(6):1888-96.
29. Honda M, Sakai A, Yamashita T, Nakamoto Y, Mizukoshi E, Sakai Y, Yamashita T, Nakamura M, Shirasaki T, Horimoto K, Tanaka Y, Tokunaga K, Mizokami M, Kaneko S, . Hokuriku Liver Study Group Hepatic ISG expression is associated with geneticvariation in interleukin 28B and the outcome of IFN therapy for chronic hepatitis C. Gastroenterology 2010, 139(2):499-509. Hokuriku Liver Study Group.
30. Huang C, Chen H, Cassidy W, Howell CD. Peripheral blood gene expression profile associated with sustained virologic response after peginterferon plus ribavirin therapy for chronic hepatitis-C genotype 1. J Natl Med Assoc 2008, 100(12):1425-33.
31. Xing TJ, Xv HT, Zhao W, Shen L, Li H, Cai RT. Application of interferon response-related gene array to the antiviral treatment outcome in chronic hepatitis C. Hepatogastroenterology 2010, 57(102-103):1257-63.
32. Martin MP, Qi Y, Goedert JJ, Hussain SK, Kirk GD, Hoots WK, Buchbinder S, Carrington M, Thio CL. IL28B polymorphism does not determine outcomes of hepatitis B virus or HIV infection. J Infect Dis 2010, 202(11):1749-53.
33. Rallon NI, Restrepo C, Naggie S, Lopez M, Del Romero J, Goldstein D, McHutchison J, Soriano V, Benito JM. Interleukin-28B gene polymorphisms do not influence the susceptibility to HIV-infection or CD4 cell decline. AIDS 2011, 25(2):269-71.
34. Caignard G, Bouraï M, Jacob Y, Tangy F, Vidalain PO. Infection-MAPping project I-MAP Inhibition of IFN-alpha/beta signaling by two discrete peptides within measles virus V protein that specifically bind STAT1 and STAT2. Virology 2009, 383(1):112-20. Infection-MAPping project I-MAP.
35. Miyoshi H, Fujie H, Shintani Y, Tsutsumi T, Shinzawa S, Makuuchi M, Kokudo N, Matsuura Y, Suzuki T, Miyamura T, Moriya K, Koike K. Hepatitis C virus core protein exerts an inhibitory effect on suppressor of cytokine signaling (SOCS)-1 gene expression. J Hepatol 2005, 43(5):757-63.
36. Brysha M, Zhang JG, Bertolino P, Corbin JE, Alexander WS, Nicola NA, Hilton DJ, Starr R. Suppressor of cytokine signaling-1 attenuates the duration of interferon gamma signal transduction in vitro and in vivo. J Biol Chem 2001, 276(25):22086-9.
37. Brand S, Zitzmann K, Dambacher J, Beigel F, Olszak T, Vlotides G, Eichhorst ST, Göke B, Diepolder H, Auernhammer CJ. SOCS-1 inhibits expression of the antiviral proteins 2',5'-OAS and MxA induced by the novel interferon-lambdas IL-28A and IL-29. Biochem Biophys Res Commun 2005, 331(2):543-8.
38. Younossi ZM, Afendy A, Stepanova M, Hossain N, Younossi I, Ankrah K, Gramlich T, Baranova A. Gene expression profile associated with superimposed non-alcoholic fatty liver disease and hepatic fibrosis in patients with chronic hepatitis C. Liver Int 2009, 29(9):1403-12.